CD274 and melanoma: After a median follow-up of 22·1 months, the objective response rate of ipilimumab plus anti-PD-1 (pembrolizumab or nivolumab) and ipilimumab monotherapy was 31% (60/193) and 13% (21/162) for patients with advanced melanoma who had previously failed anti–PD-1 or anti–PD-L1 monotherapy.